A Better Approach, for
Better Breast Cancer Trials
Breast cancer affects more women worldwide than any other cancer. Despite its prevalence, studying and improving treatment is extremely complex. Oncology studies often involve multiple cohorts, tumor types, scattered sites, and expensive medications. More importantly, breast cancer patients face debilitating symptoms that can make participation in studies difficult. That's where Signant's evidence generation solutions and deep oncology experience can help.
CONNECT WITH US đź –We Have Solutions to Help Your Study Succeed
Capture Accurate Data & Incorporate PROMS
Leverage our leading digital solutions as well as extensive clinical and eCOA science expertise to capture high-quality, reliable endpoint data. And with our deep understanding of recent FDA guidance on the use of patient-reported outcomes in oncology trials, we're prepared to help you incorporate patients' perspectives in your data capture strategy.
Gain Richer Insights
With our sensors and wearables, you can collect objective data on sleep and activity patterns, for enhanced insight into the post-treatment recovery associated with each treatment cycle. Pair with our eCOA for a continuous, real-time view of each patients’ health status.
Optimize Supply Management
Our Signant SmartSignals RTSM solution uses proprietary algorithms to optimize drug supplies for the different, complex study designs associated with breast cancer trials, and applies randomization adaptations seamlessly.
Digitalize the Entire Process
While all of our solutions can be used as standalone tools, they seamlessly integrate with one another to further enhance the accuracy and efficiency of your breast cancer study.
Signant SmartSignals eConsent uses engaging multimedia to convey complex information and allows patients to flag sections they have questions on. The solution also handles the multiple consents and protocol amendments common in breast cancer trials, limiting the risk of inspection findings.
Simplify the Consent Process
Place the Patient First
Our patient-focused approach is embedded in everything from the software to the eCOA instruments’ overall designs. For example, thoughtfully migrating instrument layouts to electronic formats to ensure ease of use, such as larger, well-spaced buttons compensate for treatment-related finger numbness.
COUNTRIES
71
76,000+
PATIENTS
18,600
SITES
STUDIES
78
I - IV
PHASES
Our Breast Cancer
Experience by the Numbers
Breast Cancer Solutions
Breast Cancer Trial Solution Resources
DOWNLOADSignant's Subject Matter Experts
MEET THE EXPERTSBreast Cancer Trial Solutions
WATCH VIDEOEnhance Your Breast Cancer Clinical Trials with Signant
PATIENT CONCIERGE
RTSM
eCOA
eCONSENT
LEARN MORE đź –LEARN MORE đź –LEARN MORE đź –LEARN MORE đź –READY TO GET STARTED?
See how Signant can support your next breast cancer clinical trial.
CONNECT WITH USSignant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.